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1. Introduction 
In recent years it has become evident that mesenchymal stem cells (MSCs), also termed 
mesenchymal stromal cells, have potent immunomodulatory effects in addition to their 
known ability of organ regeneration and recruitment to sites of injured or inflamed tissue 
(Caplan 1991; Garin, Chu et al. 2007; Nauta and Fibbe 2007; Bianco, Robey et al. 2008; Shi, 
Hu et al. 2010). While the ability of MSCs to mediate tissue and organ repair replacing 
damaged tissue has initially been attributed to their multilineage differentiation potential, it 
is now widely attributed to their ability to home to site of injury secreting cytokines and 
growth factors that mediate the repair process inducing proliferation and differentiation of 
progenitor cells (Karp and Leng Teo 2009; Hoogduijn, Popp et al. 2010; Sordi, Melzi et al. 
2010). Whether MSCs migrate from the bone marrow in case of injury or if the stem cell 
niche available in the diseased organ replaces dying cells remains to be elucidated. 
MSCs have been demonstrated to exhibit a profound immunomodulatory effect on T cells, B 
cells, and Natural Killer (NK) cells. This effect has been recently shown to be mediated via 
soluble factors, and this can be enhanced further if direct cell–cell contact between the MSCs 
and immune cells is allowed (Ren, Zhao et al. 2010). Via these factors, MSCs inhibit T cell 
proliferation (Di Nicola, Carlo-Stella et al. 2002; Aggarwal and Pittenger 2005), maturation 
and differentiation of B cells (Corcione, Benvenuto et al. 2006; Tabera, Perez-Simon et al. 
2008; Asari, Itakura et al. 2009), maturation of dendritic cells (DCs) (Nauta, Kruisselbrink et 
al. 2006),  generation of cytotoxic T cells (Angoulvant, Clerc et al. 2004) and proliferation and 
cytotoxic activity of NK cells (Rasmusson, Ringden et al. 2003; Sotiropoulou, Perez et al. 
2006; Spaggiari, Capobianco et al. 2008), while inducing regulatory T cells (Tregs) (Prevosto, 
Zancolli et al. 2007; Di Ianni, Del Papa et al. 2008; Crop, Baan et al. 2010).  
MSCs have been shown to induce immunologic peripheral tolerance, suggesting their 
potential application in a therapeutic approach for immune mediated disorders. In this 
context, MSCs can be used to support the function of standard pharmacological 
immunosuppressants to reduce their dosage or even replace such toxic 
immunosuppressants promoting long-term survival of the transplanted organ (Crop, Baan 
et al. 2009). 
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Limited information is available about the molecular mechanisms responsible for the 
immunomodulation By MSCs and there is no single mechanism responsible for their 
observed tolerogenic effect. However, MSCs have been considered to potentially work 
through multiple mechanisms and have the ability to affect immunological, inflammatory 
and regenerative pathways supporting or replacing current pharmacological agents.  
Considering their immunosuppressive properties in addition to their low inherent 
immunogenicity (Rasmusson, Uhlin et al. 2007) makes MSCs an attractive treatment option 
in cell and organ transplantation potentially improving the graft outcome and eliminating a 
long immunosuppressive treatment regimen (Ryan, Barry et al. 2005; Eggenhofer, 
Steinmann et al. 2011). Both the immunosuppressive effects of MSCs and their regenerative 
potential participate to facilitate grafting of a transplanted organ as well as repair and 
regeneration of the organ after transplantation. 
In both allogeneic hematopoietic stem cell transplantation (AHSCT) and organ 
transplantation setting, major problems exist due to the lack of suitable donors. High histo-
incompatability between donor and recipient is often associated with an increased risk of 
graft rejection or graft versus host disease which MSCs might ameliorate if infusion of MSCs 
along with the organ transplant increases organ engraftment making this immunoprivilege 
useful for transplantation. Indeed, in one of the first in vivo studies showing the 
advantageous immunosuppressive effect of MSCs, allogeneic MSCs were demonstrated to 
prolong (MHC)-mismatched skin allograft survival in baboons (Bartholomew, Sturgeon et 
al. 2002). 
Furthermore, the immunosuppressive properties of MSCs, in addition to their low 
immunogenicity features, have prompted researchers to investigate co-transplantation of 
these cells in AHSCT setting to promote hematopoietic stem cells (HSCs) engraftment and to 
prevent graft versus host reactions as well as host versus graft reactivity. Additionally, 
MSCs provide support for the growth and development of HSCs further promoting 
engraftment. In this, MSCs were shown to interact with HSCs through production of growth 
factors that influence HSCs-homing and –differentiation (Krampera, Cosmi et al. 2006). This 
effect was attributed via either cell-cell contact or production of soluble factors by MSCs 
such as the CXCL12 chemokine which may attract HSCs through its interaction with the 
CXCR4 ligand (Krampera, Cosmi et al. 2006) hence improving HSCs engraftment.  
First clinical trials have been undertaken to assess the safety of MSCs administration as well 
as a potential treatment option for graft versus host disease (GvHD). Encouraging results 
have been obtained in patients with steroid resistant GvHD and in the management of 
chronic GvHD after AHSCT. Interestingly, MSCs treatment improved the overall outcome 
and successfully attenuated GvHD in these patients (Le Blanc, Rasmusson et al. 2004; 
Ringden and Le Blanc 2011).  
MSCs were shown to attenuate graft rejection and in combination with immunosuppressive 
therapy were able to prolong cardiac allograft survival when co-administered with 
immunosuppressive therapy. Indeed, they promote donor-specific graft tolerance and 
ameliorate the alloimmune response where the use of low dose therapy alone was not 
sufficient to maintain the graft; only combination therapy with MSCs maintained the cardio 
graft (Ge, Jiang et al. 2009).  
MSCs have also been suggested as a promising cell immunotherapy tool to promote 
tolerance for organ transplants and to control allograft rejection in post-transplant therapy 
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settings facilitating both transplant acceptance and physiologic functions (Crop, Baan et al. 
2009; Dahlke, Hoogduijn et al. 2009). MSCs have also been recently shown to have an 
ameliorating effect in a model of acute lung injury were transplantation of MSCs resulted in 
a significant increase in the level of  protective/immunomodulatory  Tregs (Sun, Han et al. 
2011). Finally, clinical trials are ongoing to determine the efficacy of MSCs as an effective 
tool for the treatment of autoimmune diseases, such as multiple sclerosis, inflammatory 
bowel diseases, rheumatoid arthritis, and type 1 diabetes.  
2. The biology and originality of mesenchymal stem cells and their 
generation and expansion in vitro for therapeutic use 
MSCs are a self-renewing heterogeneous population of multipotent cells, originally isolated 
from bone marrow as shown in pioneer experiments by Friedenstein and colleagues and 
first referred to as colony-forming unit fibroblasts (Friedenstein, Chailakhyan et al. 1974). 
Since then, MSCs have been isolated from many other adult tissues such a umbilical cord 
blood, placenta, amniotic fluid, peripheral blood, adipose tissue and various other somatic 
tissues sharing the regenerative as well as the immunomodulatory properties of MSCs (In 't 
Anker, Scherjon et al. 2004; Zuk 2010; Bianco 2011) but have mainly been characterized after 
isolation from bone marrow.  
MSCs can be expanded in vitro as plastic adherent cells with a fibroblast-like morphology 
and can be differentiated into cells of mesodermal lineage (osteocytes, chondrocytes and 
adipocytes) (Pittenger, Mackay et al. 1999) as well as cells from other embryonic lineages 
(Sanchez-Ramos 2006; Schwartz, Brick et al. 2008). At present, MSCs lack a definitive marker 
and no single marker has been identified distinguishing MSCs however the International 
Society for Stem Cell Research has outlined minimal criteria to characterize human MSCs, 
these cells have been reported to be positive for CD73, CD90, CD105 and major 
histocompatibility complex class I (HLA-ABC).  They are devoid of the hematopoietic 
markers such as CD14, CD 19, CD34, CD45 and for major histocompatibility complex class 
II, (HLA-DR) (Dominici, Le Blanc et al. 2006).  
An attractive characteristic of MSCs is that they can be easily expanded maintaining a 
relatively stable phenotype and karyotype along with their potential to differentiate into 
multiple mesodermal tissues. The possibility that MSCs might undergo malignant 
transformation does exist, however this might be directly linked to the origin of the tissue. 
Interestingly, it has been shown that human bone marrow derived MSCs could be expanded 
in vitro and despite decreased proliferative capacity upon prolonged expansion and 
eventual cell senescence, no chromosomal abnormalities were detected rendering these cells 
suitable for cell therapeutic approaches (Bernardo, Zaffaroni et al. 2007).   
However, there is a general consensus that MSCs should be used at low passages when 
applied in cell therapy as chromosomal modifications and loss of function can occur after 
prolonged in vitro expansion. 
3. The Immunomodulatory properties of mesenchymal stem cells and their 
role in transplantation 
Understanding the mechanisms by which MSCs exert their immunomodulatory effects will 
have profound therapeutic implications in designing new therapies that can lead to more 
efficient use of these cells in novel treatment regimens. Currently, there is no single clear 
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mechanism which clearly clarifies the immunomodulatory effect of MSCs and several 
mechanisms which sometimes seem paradoxical, have been suggested. Several in vitro 
experimental studies have shown that the immunosuppressive effect of MSCs is sustained 
in transwell experiments suggesting that soluble factors are responsible for such inhibition 
(Di Nicola, Carlo-Stella et al. 2002; Meisel, Zibert et al. 2004; Aggarwal and Pittenger 2005; 
Gao, Wu et al. 2008; Ren, Zhang et al. 2008; Selmani, Naji et al. 2008), while other studies 
have claimed a required cell-cell contact which may be due to the use of different systems 
and cells by the individual research groups (Quaedackers, Baan et al. 2009; Ren, Zhao et al. 
2010).  
MSCs have been shown to modulate the immune response mainly by inhibiting the 
proliferation of effector immune cells preventing further damage to injured tissue allowing 
repair after injury (Uccelli, Moretta et al. 2008). Moreover, MSCs can stimulate the activation 
and proliferation of Tregs which in turn have a beneficial immunosuppressive effect (Crop, 
Baan et al. 2010).  
When MSCs home to site of tissue inflammation or injury, they release various growth 
factors  which enhance repair at site of defect including : fibroblast growth factor, epidermal 
growth factor, platelet-derived growth factor, transforming growth factor-┚, vascular 
endothelial growth factor and insulin-like growth factor (Ng, Boucher et al. 2008).  MSCs 
mediated inhibition of effector T cell proliferation seems to be dependent on the 
microenvironment. In this respect, the presence of pro-inflammatory cytokines such as IFN-
┛ activates MSCs and this was more effective for the treatment of GvHD (Polchert, Sobinsky 
et al. 2008). Indeed, it has been shown, that the immunosuppressive capacity of MSCs was 
enhanced strongly under inflammatory conditions while their differentiation capacity was 
preserved and suggested that in vitro preconditioning provides MSCs with improved 
properties for immediate clinical immune therapy (Crop, Baan et al. 2010).    
MSCs have been shown to affect almost all cell types of the immune system. It has been 
demonstrated that MSCs can alter the cytokine secretion profile of immune cells such as 
decreasing TNF-┙ and IFN-┛ secretion and increasing the secretion of suppressive cytokines 
(IL-4 and IL-10) and this shift from a pro-inflammatory to a beneficial anti-inflammatory 
response is of therapeutic advantage for the management of GvHD (Dahlke, Hoogduijn et 
al. 2009; Hoogduijn, Popp et al. 2010). Moreover, several studies have demonstrated that the 
MSCs immunoregulatory properties are partially mediated by transforming growth factor  
(TGF-┚), prostaglandin E2 (PGE2), hepatocyte growth factor (HGF) and Indoleamine 2, 3-
dioxgenase (IDO) secreted by MSCs in addition to their induction and activation of Tregs all 
of which can lead to amplification of  an effective immunosuppressive response (English, 
Ryan et al. 2009; Kim, Wee et al. 2011). 
3.1 MSC–soluble factors and immunosuppression induction  
Different studies have attributed the immunosuppressive effect of MSCs to several 
immunosuppressive factors leading to different mechanisms of immune cell inhibition. 
These include, IDO (Meisel, Zibert et al. 2004; DelaRosa, Lombardo et al. 2009), PGE2 
(Aggarwal and Pittenger 2005), TGF-┚ and HGF (Di Nicola, Carlo-Stella et al. 2002), HLA-G 
(Selmani, Naji et al. 2008), nitric oxide (Ren, Zhang et al. 2008), interleukin (IL)-10 (Gao, Wu 
et al. 2008) and haeme oxygenase-1 (Chabannes, Hill et al. 2007). One important mechanism 
is that MSCs suppression is mediated by IDO, a tryptophan catabolising enzyme (Meisel, 
Zibert et al. 2004). In this, activated T cells or NK cells produce elevated levels of IFN-┛ 
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which in turn stimulates MSCs to produce IDO. IDO metabolizes tryptophan to kynurenine 
leading to essential tryptophan depletion and accumulation of metabolites in the medium 
which in turn inhibits proliferation of activated T cells and  NK cells (Meisel, Zibert et al. 
2004). Competitive inhibition of IDO activity did not completely abrogate MSC mediated 
immunosuppression and inhibition of IFN-┛ was required for complete abrogation 
(Krampera, Cosmi et al. 2006; DelaRosa, Lombardo et al. 2009). This suggests that co-
administration of MSCs with graft T cells-derived IFN-┛ activates the immunomodulatory 
properties of MSCs. Furthermore, there is a species variation in the immunosuppressive 
mechanisms mediated by MSCs. It has been shown that while human IDO is a major 
effector molecule for MSCs immunosuppression, mouse MSCs mediate their inhibitory 
effect of immune responses via nitric oxide playing a central role in such 
immunosuppression (Sato, Ozaki et al. 2007; Ren, Zhang et al. 2008).  
3.2 MSC-immune cell interaction and immunosuppression induction  
MSCs have been demonstrated to exhibit a profound immunomodulatory effect on Tregs, 
cytotoxic and T helper cells, NK cells, B cells and dendritic cells.  
3.2.1 Regulatory T cells 
Tregs are a subset of T cells that regulate the immune response by suppressing the 
proliferation and cytokine production of effector T cells. Tregs are thus important for 
protecting our body by suppressing auto-reactive T cells (Thornton and Shevach 1998; Ng, 
Duggan et al. 2001). Tregs were shown to be upregulated in the presence of MSCs 
suggesting that MSCs constitute a suitable niche for Tregs (Crop, Baan et al. 2010). MSCs 
have been suggested to play a role in Tregs recruitment, regulating and maintaining the T 
regulatory phenotype and function over time (Prevosto, Zancolli et al. 2007; Di Ianni, Del 
Papa et al. 2008).  Tregs induction has been suggested to be mediated by PGE2, synthesized 
by cyclooxygenase enzymes (COX) which are expressed by MSCs (Le Blanc and Ringden 
2007). Furthermore, Treg induction has been shown to be mediated by direct cell-cell contact 
between MSCs and CD4+ T cells and the presence of soluble MSC derived factors such as 
TGF-┚1 and PGE2 (English, Ryan et al. 2009). In a recent interesting study by (Sundin, 
D'Arcy et al. 2011) it was demonstrated for the first time that MSCs share features with 
regulatory T cells , such as the expression of the Tregs specific transcription factor FOXP3 
(Yagi, Nomura et al. 2004) at variable levels. However,  the MSC immunosuppressive 
function is not as tightly linked to FOXP3 expression as is the case for Tregs (Sundin, D'Arcy 
et al. 2011).  
3.2.2 Cytotoxic T cells and T helper cells 
MSCs were shown to inhibit the proliferation of CD4+ T helper cells (Di Nicola, Carlo-Stella 
et al. 2002; Aggarwal and Pittenger 2005). In addition to indirect inhibitory factors produced 
by MCSs such as TGF-┚1, HGF, IL-10, IFN-┛ and TNF-┙, there is evidence that cell-
membrane interaction between MCSs and T helper cells (Quaedackers, Baan et al. 2009) via 
the intracellular adhesion molecule (ICAM-1) or vascular cell adhesion molecule (VCAM-1) 
play a crucial role in such immunosuppression (Ren, Zhao et al. 2010). MSCs have also been 
shown to suppress the induction of cytotoxic T cell response to allo-antigens (Angoulvant, 
Clerc et al. 2004). However, once cytotoxic T cells are activated, MSCs show no inhibitory 
effect (Rasmusson, Ringden et al. 2003; Le Blanc and Ringden 2007). On the other hand, it is 
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not clear how helper and cytotoxic T cells affect MSCs development and function. It has 
been shown that MSCs have a low immunophenotype as they express low levels of HLA 
class I, no HLA class II, no co-stimulatory molecules such as CD80 and CD86, and therefore 
do not induce immune responses (Beggs, Lyubimov et al. 2006; Rasmusson, Uhlin et al. 
2007). This should make MSCs transplantable across HLA barriers (Le Blanc, Tammik et al. 
2003). However, in contrast to these data, there is evidence that MSCs are immunogenic and 
can induce memory T-cell responses both in animals (Badillo, Beggs et al. 2007) and human 
studies (Nauta, Westerhuis et al. 2006). Furthermore, it has recently been reported that 
MSCs are susceptible for lysis by CD8+ cytotoxic T cells (Crop, Korevaar et al. 2011). 
Designing tools to escape allogeneic MSCs destruction by cytotoxic T cells should render 
MSCs a promising therapeutic option for transplantation across MHC barriers.   
3.2.3 Natural Killer cells  
MSCs have been shown to inhibit  NK cell proliferation, and cytotoxicity (Sotiropoulou, 
Perez et al. 2006). It has been demonstrated that MSCs can mediate this inhibitory effect 
trough inhibition of cytokine production in addition to the central role played by IDO and 
PGE2 (Spaggiari, Capobianco et al. 2008). Inversely, it has been shown that MSCs are 
susceptible for lysis by NK cells (Spaggiari, Capobianco et al. 2006; Crop, Korevaar et al. 
2011) as MSCs express the activating NK cell-receptor ligands NKG2D and UL16 (Poggi, 
Prevosto et al. 2007). Moreover, intravenously administered MSCs have been demonstrated 
to disappear within days after infusion in immunocompetent mice (Popp, Eggenhofer et al. 
2008). It is possible that lysis by cytotoxic T cells (and not NK cells) is responsible for the 
disappearance of the infused MSCs (Eliopoulos, Stagg et al. 2005). The demonstration of 
tumour engraftment after administration of autologous MSCs in immunodeficient mice (NK 
cells intact) further strengthens this possibility.  
3.2.4 B cells  
MSCs have been shown to suppress B cell terminal differentiation (Asari, Itakura et al. 2009) 
and modulate their function (Corcione, Benvenuto et al. 2006; Tabera, Perez-Simon et al. 
2008). Human MSCs were shown to inhibit antibody production induced in vitro by allo-
stimulation (Comoli, Ginevri et al. 2008; English, French et al. 2010). They have the ability to 
regulate Immunoglobulin production by B cells through soluble factors affecting B cells 
directly or through an indirect MSCs effect by altering the amount of free alloantigen due to 
the overall suppression of graft damage (Ge, Jiang et al. 2009).  
3.2.5 Dendritic cells 
MSCs inhibit monocyte maturation into dendritic cells (Jiang, Zhang et al. 2005), the most 
potent antigen presenting cells,  inhibiting their migration to lymph nodes and thereby 
reducing their ability to activate allo-reactive T cells (Aggarwal and Pittenger 2005). In 
this, MSCs were shown to reduce secretion of pro-inflammatory cytokines such as IFN-┛, 
IL-12 and TNF-┙ by DCs  while IL-10, a suppressive cytokine, was increased leading to 
the inhibition of DCs maturation and the inability to activate allo-reactive T cells resulting 
in a state of an immunologic tolerance. The inhibitory effect of MSCs on DC 
differentiation is mainly mediated through cell-cell contact involving activation of the 
Notch signalling pathway (Li, Paczesny et al. 2008) as well via soluble factors (Nauta, 
Kruisselbrink et al. 2006). Moreover, PGE2 produced by MSCs following TNF-┙ or IFN-┛ 
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stimulation blocks differentiation of monocytes into DCs and stimulates macrophages to 
produce Il-10.   
3.3 MSCs-Galectins and immunosuppression induction 
Recently, Sioud et al  (Sioud, Mobergslien et al. 2010; Sioud 2011)and Gieseke et al (Gieseke, 
Bohringer et al. 2010) have described another mechanism of MSCs immunosuppression that 
involves a family of beta galactosidase-binding proteins named Galectins which are 
involved in immune tolerance (Garin, Chu et al. 2007). It has been demonstrated that 
Galectin-1, Galectin-3, Galectin-8 and Galectin-9 are constitutively expressed by human 
bone marrow MSCs with Galectin-1 and Galectin -3 being further secreted and expressed on 
the outer plasma membrane (Wada and Makino 2001). New evidence has shown the 
involvement of Galectin-3 as a regulator of MSCs immunosuppression function inhibiting 
allogeneic T cell proliferation by MSCs (Sioud 2011). This group demonstrated that gene 
knockdown of Galectin-3 resulted in less immunosuppressive effect on T cell proliferation 
(Sioud, Mobergslien et al. 2010). Galectins were also shown to regulate the secretion of pro-
inflammatory cytokines and  promote expansion of IL-10 producing peripheral Tregs  
(Sioud 2011). Gieseke et al have also reported that galectin-1 is expressed by MSCs and has 
immunosuppressive activity on both CD4+ and CD8+ T cells (Gieseke, Bohringer et al. 2010). 
4. Clinical prospects of mesenchymal stem cells  
Currently suggested clinical uses of MSCs include; differentiation and repairing of damaged 
tissue e.g. in osteogenesis imperfecta, promoting hematopoietic cell engraftment in AHSCT 
e.g. in leukaemia and their immunosuppressive abilities in autoimmune-induced 
inflammatory bowel disease, GvHD induced upon allogeneic cell or organ transplantation 
as well as autoimmune diseases. Treating autoimmunity with MSCs was first investigated 
for experimental autoimmune encephalomyelitis as a model for multiple sclerosis in 
preclinical studies followed by collagen-induced arthritis, autoimmune type 1 diabetes, 
experimental colitis and lupus nephritis (Uccelli and Prockop 2010). 
Still, very little is known about the mechanisms underlying the MSCs immunomodulatory 
effect in vivo and survival of MSCs upon injection and whether they remain present after 
systemic injection or local transplantation remains unresolved.  However, the clinical 
studies performed so far look encouraging but still the mechanisms as to how the MSCs 
regulate immune cells in vivo are still missing. Furthermore, direct methods to assess MSCs 
mobilization and homing in response to injury or inflammation is essential to eventually 
understand the underlying mechanism (Karp and Leng Teo 2009).  
MSCs are immune-privileged and were shown in most studies to ‘escape’ the immune 
system and be tolerated when transplanted across MHC barriers engrafting and failing to 
induce an immune response. It is important to mention that most of these clinical studies 
have used MSCs from HLA-identical or near identical donors (Le Blanc and Ringden 2007).  
It has been reported that AHSCT recipients have specific tolerance, immune-
unresponsiveness, directed towards MSCs but not to other cells from the MSC donor 
(Sundin, Barrett et al. 2009). This suggests that totally HLA mismatched MSCs from one 
donor can be expanded ex vivo, cryopreserved and used for the treatment of multiple 
patients. Furthermore, the inability of MSCs to induce donor specific tolerance suggests that 
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MSCs co-transplantation with a solid organ most probably facilitates engraftment through 
the immunosuppressive action of MSCs and not by inducing specific tolerance to the 
transplant (Sundin, D'Arcy et al. 2011).  
4.1 Graft versus Host Disease 
GvHD occurs in donated organ recipients and patho-physiologically presents itself as 
damage in skin, mucosa, gastrointestinal tract, the liver, connective tissue and exocrine 
glands. It is considered chronic when it persists more than 100 days after transplantation 
and it is distinguished from acute GvHD which often cannot be ameliorated because of a 
coexistent immunosuppression.   It results from the attack of donor own T cells in the graft 
on recipient tissues after activation by recipient MHC molecules as well as activation of 
cytotoxic T cells, antigen presenting cells and NK cells. In GvHD the observation of an 
increased secretion of pro-inflammatory cytokines such as TNF-┙, IFN-┛, IL-1, IL-2 and IL-
12 suggests that therapeutic approaches to inhibit these cytokines should lead to a decreased 
severity of GvHD (Aggarwal and Pittenger 2005).  
The immunosuppressive effects of MSCs have been evidenced in a successful clinical trial 
reported by Ringden et al (Ringden and Le Blanc 2011) in patients presented with acute 
GvHD after AHSCT and resistant to conventional immunosuppressive therapy. This study 
showed a dramatic improvement after MSCs infusion with acute GvHD disappearing 
completely in patients with steroid resistant GvHD suggesting that MSCs could be 
considered as a promising alternative immunosuppressive therapy with improved long 
term outcome for the treatment of GvHD (Le Blanc, Rasmusson et al. 2004; English, French 
et al. 2010; Ringden and Le Blanc 2011; Tolar, Villeneuve et al. 2011).  
4.2 Type 1 diabetes  
MSCs have been suggested as a prospective cell therapy of autoimmune type 1 diabetes 
known to be associated with an inflammation in the pancreas and degeneration of ┚ cells. In 
a preclinical study, it has been shown that co-transplantation of bone marrow cells and 
syngeneic or allogeneic MSCs initiated endogenous pancreatic regeneration and improved 
blood glucose levels in streptozotocin induced diabetic mice (Ulicna, Danisovic et al. 2009). 
The success in the treatment was suggested to be due to MSCs aiding in the regeneration of 
recipient derived pancreatic beta cells, as well as maintaining the ┚ cell reserve through 
MSC inhibition of T cell-mediated immune responses against the newly formed ┚ cells 
preventing further cell degeneration (Voltarelli, Couri et al. 2007; Couri and Voltarelli 2009; 
Ulicna, Danisovic et al. 2009; Sordi, Melzi et al. 2010). Hence, despite of the persisting hostile 
autoimmune response in the pancreas, when MSCs are applied at an early stage of the 
disease they potentially protect and allow the endogenous regeneration of the remaining 
intact ┚ cell reserve.  
4.3 Solid organ transplantation  
In solid organ transplantation (e.g. liver transplant), rejection of a transplanted organ is 
typically caused by induction of T cell proliferation and presentation of allo-antigens to 
naive and memory T cells by antigen presenting cells (both host and donor) leading to 
activation and differentiation into effector T cells (Popp, Renner et al. 2009). Both the 
regenerative and immunomodulatory properties of MSCs are of medical importance in 
organ transplantation studies. MSCs have been shown to home to site of allograft and help 
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the body accommodate the new organ through immunosuppression or preventing rejection 
and acquisition of a state of tolerance (English, French et al. 2010). Furthermore, the 
regenerative properties of MSCs possibly maintain the organ to be transplanted stretching 
its lifespan in case of delayed transplantation (Hematti 2008; Hoogduijn, Popp et al. 2010). 
For MSCs to be used as a sole therapy or as a combination therapy replacing 
immunosuppressive drugs, reducing the burden on the patient and the risk for long term 
side effects, further investigation will be needed to fully explain the immunomodulatory 
properties of MSCs. However, MSCs were shown to increase immunosuppression when co-
administered complementing the therapy (Sundin, D'Arcy et al. 2011). In this regard, an  
interesting animal study of allogeneic heart graft transplantation that MSCs combined with 
the immunosuppressive drug mycophenolate mofetil (MMF) promoted the elimination of 
activated T cells in secondary lymphatic organs, delayed antigen presenting cells activation, 
and protected the graft from cellular infiltration by modulating the endothelium 
(Eggenhofer, Steinmann et al. 2011).  
5. Quality considerations and regulations in MSC based therapy 
Clinical use of MSCs for cellular therapeutic approaches will require that the bio-safety of 
these cells has to be adequately optimised. This requires the absence of chromosomal, 
functional, and phenotypical alterations in ex vitro expanded MSCs before considering their 
injection in patients. The safety of these cells has to be guaranteed upon their administration as 
immunocompromised patients might have an increased risk of tumour induction or the 
potential risk of stimulating the growth of a previously undetected cancer. The risk of 
tumorigenicity and genomic instability remains  an obstacle for any given stem-cell based 
therapy product and will have to be adequately assessed prior to approval for human use 
(Dittmar, Simann et al. 2010).  In this respect, the first clinical trials have been undertaken to 
assess the safety of MSC administration and potential treatment options for GvHD and it has 
been reported that autologous and allogeneic MSCs are safe to be injected in patients with life 
threatening acute GvHD not responding to conventional immunosuppressive therapy without 
acute toxicity and no signs of ectopic tissue formation (Lazarus, Koc et al. 2005).  
MSCs administered for therapy might carry viruses (e.g. herpes simplex virus, cytomegalo 
virus (CMV), Epstein-Barr Virus (EBV)) transmitted from the donor to the host tissue 
especially when the patient is immunocompromised. Interestingly, MSCs were shown to 
exert differential effects on alloantigen and virus-specific T cell responses (Karlsson, 
Samarasinghe et al. 2008). In this regard, it has been reported that despite MSC infusion as a 
cellular immunotherapy for GvHD, effector functions of virus specific T cells were retained 
with very little effect on T cell responses to pathogenic CMV and EBV contrasting the strong 
immunosuppressive effect on allo-reactive T cells suggesting that MSCs to be a promising 
cellular immunotherapy (Karlsson, Samarasinghe et al. 2008). This is an important 
advantageous aspect of MSCs therapy especially since after allogeneic organ transplantation; 
infections are a major cause of morbidity and mortality in immunocompromised patients. 
Therefore, MSCs can be safely administered without exacerbating their susceptibility to 
infectious pathogens.  
Currently large clinical trials are being carried out in using MSCs for the treatment of 
autoimmune diseases including diabetes as well as to treat or ameliorate symptoms of 
GvHD. Further, clinical trials are also testing the MSCs ability to facilitate the prevention of 
the rejection upon organ transplantation thereby reducing or completely eliminating the 
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need for immunosuppressive therapies. Reviewing the clinical trials registered by the U.S. 
National Institutes of Health (NIH) in the United States and around the world (U.S. National 
Institutes of Health, http://clinicaltrials.gov/), 168 registered studies (with a start date 
between September 2004 and March 2011) were found upon entering the search criteria 
mesenchymal + stem + cells including clinical trials in regenerating organs (e.g. bone 
fractures, diabetic foot and foot ulcer), liver failure, the administration of MSCs for the 
treatment of type 1 Diabetes Mellitus as well as Type 2, acute GvHD including studies with 
patients who have failed to respond to steroid therapy (or with steroid resistance) and poor 
graft function. In addition to these trials, ongoing clinical studies investigating the safety 
and efficacy of MSCs promoting engraftment of allogeneic hematopoietic stem cells are in 
hand (Le Blanc, Rasmusson et al. 2004). 
The translation into cellular therapies satisfying safety and efficacy criteria by the regulatory 
authorities will have to ensure the identity, purity, potency, and lack of tumorigenicity. 
Questions regarding the expansion of MSCs in vitro and the passage at which they are used 
as well as the culture conditions containing foetal calf serum, optimal dosing, timing and 
HLA matching still remain to be answered (Le Blanc, Samuelsson et al. 2007; Sundin, 
Ringden et al. 2007). 
Scientists and clinicians should adhere to local, national and international guidelines and 
regulations that govern transfer of cells into patients. The clinical trial and the eventual cell 
therapeutic product is assessed and approved by a national regulatory agency, such as the 
European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA).The 
International Society for Stem Cell Research (ISSCR) has published guidelines for the clinical 
translation of stem cells emphasising on the scientific, clinical and ethical issues that should 
be addressed for a responsible translation of basic stem cell research into suitable clinical 
applications. The guidelines give attention to the main areas of clinical translational stem 
cell research namely, cell processing and manufacture, the necessity of preclinical studies 
and clinical research promoting maximum safety and quality of the cells to be used (Hyun, 
Lindvall et al. 2008). 
6. Conclusion  
Understanding the immunomodulatory properties of MSCs and possibly identifying genes 
that regulate MSC inhibitory function, and genes regulating inflammation which play a 
major role in transplant rejection and inflammatory processes should help in developing 
applicable MSC based cellular therapies for solid organ transplantation, GvHD and 
autoimmune diseases.   
The currently available data, in vitro and in vivo, suggest that MSCs can be applied in a 
wide range of clinical approaches, ranging from tissue repair and regeneration, drug or gene 
delivery to injured tissue, treatment and prevention of GvHD and AHSCT engraftment 
offering a promising option for treating autoimmune mediated disorders as well as organ 
transplantation. Administration of MSCs provides novel modalities for the treatment of 
patients with allograft rejection with fewer side effects than existing immunosuppressive 
therapies following organ transplantation. 
There is an enormous amount of excitement and the scope of possible stem cell based 
therapies has expanded in the recent years due to rapid advances in stem cell research.  But 
today the range of diseases where stem cell treatments have been shown to be beneficial in 
responsibly conducted clinical trials is still extremely restricted.  
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The best defined and most extensively used is hematopoietic stem cell transplantation in 
blood malignancies and aplastic anaemia. To design safe and effective cellular therapies, the 
long term effects of MSCs injection will still need to be shown in relevant clinical trials and 
further studies are needed to optimize cell-dosing, time of injection and the combination 
with immunosuppressive drugs to confirm both efficacy and safety of this cell therapy, are 
still needed within the careful regulations of the EMA and FDA.  
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